🇧🇪 ARGX.BR — argenx SE

Salud Compra fuerte
← Volver

Precio actual

815,60 EUR

Máx. histórico

912,40

63 días

Caída desde máximo

-10,61%

Rango 52 semanas

568,40 – 925,00

Variación hoy

+0,07%

Cierre anterior

815,00

Rango de hoy

812,40 – 835,80

Volumen hoy

109.168

Peor caída histórica

-39,26%

21/07/2023 → 21/12/2023

Recuperado en 262 días

Volatilidad anualizada ⓘ

43,77%

Información
Nombre completo
argenx SE
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
1.863
PER ⓘ
32,82 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
998,93 EUR (puede no estar actualizado)
Primera cotización
10/07/2014
Precio actualizado
hace 17 horas
Sobre la empresa

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
14/05/2015 9,56 9,60 9,56 9,60 +1,59% 0,42% 1.962
13/05/2015 9,36 9,50 9,35 9,45 +1,50% 1,60% 3.239
12/05/2015 9,44 9,44 9,30 9,31 -0,43% 1,48% 2.160
11/05/2015 9,30 9,46 9,30 9,35 -0,53% 1,72% 6.069
08/05/2015 9,15 9,40 9,15 9,40 +2,73% 2,73% 4.906
07/05/2015 9,31 9,31 9,15 9,15 -2,66% 1,72% 8.104
06/05/2015 9,45 9,45 9,24 9,40 +0,53% 2,22% 5.882
05/05/2015 9,20 9,51 9,20 9,35 +1,63% 3,37% 18.395
04/05/2015 9,10 9,24 9,02 9,20 +0,88% 2,42% 7.871
30/04/2015 9,10 9,20 9,05 9,12 -0,33% 1,65% 7.081
29/04/2015 9,16 9,21 9,15 9,15 -0,54% 0,66% 1.575
28/04/2015 9,15 9,21 9,00 9,20 +1,32% 2,30% 9.776
27/04/2015 9,18 9,18 9,00 9,08 -0,44% 1,96% 8.061
24/04/2015 8,97 9,16 8,97 9,12 +1,33% 2,12% 15.962
23/04/2015 9,00 9,21 8,92 9,00 +0,90% 3,22% 51.666
22/04/2015 8,95 8,95 8,92 8,92 +0,22% 0,34% 2.177
21/04/2015 8,95 8,95 8,90 8,90 +0,00% 0,56% 4.653
20/04/2015 8,80 8,97 8,80 8,90 +1,14% 1,93% 2.580
17/04/2015 8,99 8,99 8,60 8,80 -2,00% 4,34% 7.491
16/04/2015 9,00 9,00 8,86 8,98 -0,11% 1,56% 2.472
15/04/2015 9,04 9,08 8,92 8,99 -0,55% 1,77% 4.970
14/04/2015 9,15 9,15 9,01 9,04 +0,44% 1,53% 11.317
13/04/2015 9,04 9,05 8,91 9,00 -0,44% 1,55% 12.172
10/04/2015 9,10 9,13 9,00 9,04 -1,09% 1,43% 5.065
09/04/2015 8,86 9,14 8,84 9,14 +1,56% 3,39% 14.478
08/04/2015 8,95 9,10 8,93 9,00 +1,01% 1,90% 6.274
07/04/2015 8,81 8,98 8,81 8,91 +0,34% 1,93% 2.958
02/04/2015 9,03 9,03 8,70 8,88 -2,09% 3,65% 6.917
01/04/2015 9,03 9,07 9,02 9,07 -0,11% 0,55% 1.113
31/03/2015 9,20 9,20 9,00 9,08 -0,44% 2,17% 8.085